Trinity College Dublin researchers have developed a promising approach to combat MRSA by targeting the immune suppressor IL-10 during vaccine delivery. As MRSA continues to evade traditional antibiotics, this innovative strategy offers new hope for effective vaccines against S. aureus infections, which are major contributors to mortality worldwide.
Researchers have made significant progress in the fight against MRSA by enhancing vaccine efficacy through targeting IL-10, an immune-suppressing molecule. Their findings suggest that neutralizing IL-10 can potentiate the immune response and aid in the clearance of the bacterium in animal models. Scientists from Trinity College Dublin have taken a leap forward in understanding how we might fight back against the potentially deadly MRSA bacterium.
They have shown in an animal model that targeting a key suppressive immune molecule (IL-10) during the delivery of a vaccine improves the ability of the vaccine to protect against infection. The bacterium Staphylococcus aureus is one of the leading causes of community- and hospital-acquired bacterial infection, and is associated with over one million deaths worldwide each year. Unfortunately, antibiotics are becoming increasingly less effective against this bacterium with the antibiotic-resistant form, MRSA, responsible for the highest number of deaths in high-income countries that are attributable to antimicrobial-resistant bacterial infections.
Immunological Insights and Vaccine Enhancem.